Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.

about

Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.

Item

http://www.wikidata.org/entity/Q55121518

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Therapy susceptible germline-r ...... ma (MANEC) of the small bowel.

@en

Therapy susceptible germline-r ...... adeno-neuroendocrine carcinoma

@nl

type

Item

label

Therapy susceptible germline-r ...... ma (MANEC) of the small bowel.

@en

Therapy susceptible germline-r ...... adeno-neuroendocrine carcinoma

@nl

prefLabel

Therapy susceptible germline-r ...... ma (MANEC) of the small bowel.

@en

Therapy susceptible germline-r ...... adeno-neuroendocrine carcinoma

@nl

P1476

Therapy susceptible germline-r ...... oma (MANEC) of the small bowel

@en

P2093

A Brunn

http://www.w3.org/2001/XMLSchema#string

A Bunck

http://www.w3.org/2001/XMLSchema#string

C Bruns

http://www.w3.org/2001/XMLSchema#string

C Heydt

http://www.w3.org/2001/XMLSchema#string

D Waldschmidt

http://www.w3.org/2001/XMLSchema#string

H Alakus

http://www.w3.org/2001/XMLSchema#string

H Göbel

http://www.w3.org/2001/XMLSchema#string

L Tharun

http://www.w3.org/2001/XMLSchema#string

M Daheim

http://www.w3.org/2001/XMLSchema#string

M Schmidt

http://www.w3.org/2001/XMLSchema#string

P2860

Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas

Genome maintenance mechanisms for preventing cancer

A multicenter study to validate the reproducibility of MSI testing with a panel of 5 quasimonomorphic mononucleotide repeats.

Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.

Cancer risks among BRCA1 and BRCA2 mutation carriers.

CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.

P2888

s12876-018-0803-1

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1186/S12876-018-0803-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

A Quaas

P577

2018-05-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104333113

http://www.w3.org/2001/XMLSchema#string

P698

29855275

http://www.w3.org/2001/XMLSchema#string

P932

5984468

http://www.w3.org/2001/XMLSchema#string